HARP — Harpoon Therapeutics Share News
0.000.00%
Last trade - 00:00- $492.35m
- $469.57m
- $31.92m
Harpoon Therapeutics jumps on positive interim data in blood cancer trial
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber
U.S. STOCKS ON THE MOVE-Microsoft, Aptevo, Rivian
Harpoon rises over positive interim data in early-stage blood cancer trial
Brief: Harpoon Therapeutics Says Presents Updated Interim Results At ASH 2022 For Novel T Cell Engager Hpn217 In Relapsed/Refractory Multiple Myeloma
Brief: Harpoon Receives Notice Of Delisting From Nasdaq
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Harpoon Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Harpoon Therapeutics To Present Interim Results From Phase 1 Trial Of HPN217 At The 64th ASH Meeting
Brief: Harpoon Therapeutics Appoints Lauren Silvernail To Board Of Directors
Harpoon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP-Isoplexis, Seer, Wesco International
Brief: Harpoon Therapeutics Inc - QTRLY Loss Per Share $0.53
Pains and gains for cancer drugmakers ahead of industry meet
Brief: Harpoon Presents Interim Data From Ongoing Dose Escalation Portion Of T Cell Engager Hpn328 Clinical Trial At 2022 Asco Annual Meeting
U.S. RESEARCH ROUNDUP-Humacyte, Hyatt Hotels, Poseida Therapeutics
Harpoon Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Harpoon Therapeutics And Roche To Collaborate On Clinical Trials To Study Novel Immuno-Oncology Combination For Small Cell Lung Cancer